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Abstract: In vitro high-throughput screening was carried out in order to detect new 
activities for old drugs and to select compounds for the drug development process 
comprising new indications. Tebrophen, a known antiviral drug, was found to inhibit activities 
on inflammation and cancer related targets. In primary screening this semisynthetic 
halogenated polyphenol was identified to inhibit the activities of kinases ZAP-70 and Lck 
(IC50 0.34 µM and 16 µM, respectively), as well as hydrolase DPPIV (at 80 µM 41% 
inhibition). Next, it showed no cytotoxic effects on standard cell lines within 24 h. 
However, tebrophen slowed propagation of breast cancer (MDA-MB-231), osteosarcoma 
(U2OS) and cervical carcinoma (HeLa), through at least 35 population doublings in a  
dose-dependent manner. It completely stopped the division of the prostate cancer (PC3) 
cell line at 50 µM concentration and the cells entered massive cell death in less than 20 days. 
On the other hand, tebrophen did not influence the growth of normal fibroblasts. 
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According to the measured oxidative burst and estimated in silico parameters its direct 
antioxidative ability is limited. The obtained results indicate that tebrophen can be 
considered a promising lead molecule for generating more soluble derivatives with specific 
anticancer efficacy. 




BDE: bond dissociation enthalpy HAT: hydrogen atom transfer 
HTS: high-throughput screening IP: ionization potential 
PDs: population doublings PMA: phorbol-12-myristate acetate 
RSA: radical scavenging activity SET: single electron transfer 
TEB: tebrophen  
1. Introduction 
In order to acquire new drug applications, systematic screening of a unique compound library [1], 
was carried out on different biological targets [2]. This high-throughput screening (HTS) started  
in silico and proceeded in vitro [3,4]. By applying this approach, tebrophen (3,3',5,5'-tetrabromobiphenyl-
2,2',4,4'-tetrol, Figure 1), a drug known for the treatment of viral eye diseases, was found to inhibit 
activities of inflammation and cancer related targets, such as tyrosine kinases Lck and ZAP-70, and 
hydrolase Dipeptidyl peptidase IV (DPPIV/CD26), recently extensively studied [5]. 
Figure 1. Polyphenolic structure of tebrophen (3,3',5,5'-tetrabromobiphenyl-2,2',4,4'-tetrol). 
The trans (left) and cis conformers are of similar stability.  
 
Non-receptor tyrosine kinases are important components of signalling pathways [6]. Lck, p56 
kinase participates in T-cell signal transduction [7–9]. Immunoreceptor Tyrosine Activation Motif 
(ITAM)-sequences of CD3 subunit and ζ-chain of T-cell receptor are phosphorylated by Lck. This 
phosphorylation is a prerequisite for ZAP-70 kinase activity, binding to ITAM and subsequent 
phosphorylation of proteins in the cascade that enables further downstream signalling. The final result 
of this process is proliferation and differentiation of T-cells, particularly due to overexpression of 
interleukine-2 (IL-2) and other cytokines [10]. Knowledge about ZAP-70 expression in malignant 
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neoplasms [11] is still scarce. ZAP-70 is expressed by many lymphoma types and correlates with the 
immunoglobulin heavy-chain variable region gene mutational status in chronic leukemia and in  
non-Hodgkin and Hodgkin lymphoma. Polyphenols have been reported to have multiple effects on 
these and related kinases (Src and cyclin-dependent) and represent valuable starting point for further 
investigations of potential therapeutic interventions in this sense [12]. Our experience in HTS 
assessment of the inhibitory effects of polyphenolic compounds on kinases [13,14], was valuable for 
the verification and follow-up of the tebrophen afterward screening. 
The peptidase DPPIV is also important in T cell activation, immune functions, signal transduction 
and apoptosis [15,16]. It interacts with antigen presenting cell, and regulates cytokine and chemokine 
function [17]. DPPIV plays an important role in diabetes, obesity, anxiety, rheumatoid arthritis, 
multiple sclerosis, cancer, autoimmune diseases and AIDS [5,18–20]. It acts by removing N-terminal 
dipeptides from proline-containing peptides such as incretins [21,22], some neuropeptides and 
vasoactive peptides [23,24]. This enzyme was extensively screened and investigated by the authors, 
due to its pleiotropic roles [3]. Recently, polyphenols have been reported to inhibit DPPIV at the μM 
level [25]. 
The drug tebrophen (Figure 1) was a very promising hit after all screening and validation 
procedures. Moreover, the compound was not cytotoxic in the standard cell assays after 24 h, but it has 
shown very interesting activity in cell based and functional assays applied to the determination of 
potential antiproliferative/anticancer properties. In order to assess cell specificity, we investigated the 
influence of tebrophen on the growth dynamics [population doublings (PDs)] of normal human 
fibroblasts and of a few specific cancer cell lines in which inhibition of such targets may reduce or 
even stop their propagation. The observed antiproliferative activity of tebrophen, against prostate 
cancer cells particularly, is likely specific, target related according to in silico and in vitro estimations 
of its limited direct antioxidative capacity. 
2. Results  
2.1. Docking Pose of Tebrophen within DPPIV Catalytic Site 
By the FlexX/DrugScore molecular docking procedure tebrophen was predicted to bind within the 
catalytic site of DPPIV placed at the interface of its β-propeller and αβ-hydrolase domains [26]. 
Although not occupied the S1 pocket close to the DPPIV catalytic Ser630-Asp708-His740 triad, 
tebrophen was recognized by H-bond interactions with DPPIV residues Glu205-Glu205 motif, Tyr547 
and Arg125 of the S2 pocket (Figure 2). It was, however, scored lower as compared with the reference 
inhibitor valine-pyrrolidide as well as other competitive reversible non-covalent inhibitors [3]. 
2.2. In Vitro Inhibition of ZAP-70, Lck kinase and DPPIV 
According to the results obtained using the standard ELISA method for kinases [27,28], tebrophen 
showed inhibition of ZAP-70 and Lck tyrosine kinase activities. It inhibited ZAP-70 and Lck kinase 
activities in a dose response manner at μM levels (Figure 3A). Tebrophen inhibition of Lck kinase was 
similar to the one obtained for natural flavonoids apigenin, myricetin, and quercetin [13]. Inhibition of 
DPPIV activity by tebrophen at 80 µM concentration was 41%. 
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Figure 2. Molecular binding of tebrophen within the active site of DPPIV in comparison 
with the inhibitor valine-pyrrolidide coloured in magenta (PDB 1N1M [26]). 
 
Figure 3. Tebrophen inhibits (A) ZAP-70 and Lck kinase activities with IC50 values of 
0.34 μmol/L and 16 μmol/L, respectively and (B) oxidative burst stimulated with PMA or 
zymosan with IC50 values of 28 μmol/L and 62 μmol/L, respectively.  
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2.3. Oxidative Burst 
Influence of tebrophen on oxidative burst upon stimulation with PMA or zymosan [29] was 
measured in vitro on human polymorphonuclear (PMN) cells. The luminescence signal showed μM 
inhibitory effect of tebrophen on oxidative burst in a dose response manner (Figure 3B). 
2.4. Cytotoxicity Assay 
The in vitro cellular MTS cytotoxicity test [30] showed no significant inhibition of cell proliferation/ 
metabolism within 24 h for the human (THP-1 and HepG2) and animal (CHO, COS-7) standard cancer 
cell lines, by Tebrophen in concentrations up to 50 μM (data not shown, available upon request). 
2.5. The Effects of Tebrophenon on Cell Cultures Proliferation 
2.5.1. Normal Human Skin Fibroblasts NF (Primary Cells) 
Growth of the normal human skin fibroblasts NF [31,32] was followed in the presence of 50 µM 
tebrophen or 1% DMSO solvent only as a control. These cells reached senescence at PD ~55 (Figure 4A). 
For this experiment cells were seeded at PD 27 and maintained in the culture until PD 41. During this 
period they demonstrated a young phenotype and exponential growth. Tebrophen at 50 μM concentration 
did not influence NF fibroblasts growth rate or viability (Figure 4B). The NF fibroblasts also maintained 
normal morphology and showed no signs of stress over this period (~14 population doublings). 
Figure 4. (A) Growth of NF fibroblasts starting at PD 27. Tebrophen (TEB) at 50 µM 
concentration did not influence NF fibroblasts growth rate as well as (B) their viability and 
morphology. Cells were documented at PD 34. Bar is equivalent to 100 µm.  
 
Molecules 2012, 17 7869 
 
 
2.5.2. Neonatal Foreskin Fibroblasts MJ90 (Primary Cells) 
We also performed preliminary growth analysis of normal human male fibroblasts MJ90 over  
8 days in culture. MJ90 neonatal foreskin fibroblasts were obtained from the Pereira-Smith laboratory 
(Barshop Institute for Longevity and Aging Studies, UTHSCSA, San Antonio, TX, USA) [31]. Cells 
were grown in culture under standard conditions over 8 days in the presence of 0 μM (control), 50 μM 
tebrophen and 100 μM tebrophen when photographed (Figure 5). During this time control cells and 
cells under 50 μM tebrophen reached confluency, showed no difference in growth potential (2.35 and 
2.23 PD respectively) or morphology. Cells under 100 μM tebrophen showed reduced growth potential 
(1.46 over prolonged growth of 11 days) and moderately enlarged morphology. 
Figure 5. Growth of normal fibroblasts MJ90 in culture under standard conditions without 
tebrophen (TEB) and with 50 μM and 100 μM concentrations of tebrophen over 8 days. 
Bar is equivalent to 100 µm.  
 
Following observation that tebrophen has no effect on proliferation and viability of normal  
human skin fibroblasts in physiologically tolerant concentration (50 μM), we focused our interest on 
tebrophen as a potential anticancer agent. We studied the effect of tebrophen on a few frequently used 
cancer cell lines such as MDA-MB-231 [33,34], PC3 [35], U2OS [32,36] and HeLa [37,38]. 
2.5.3. Breast Adenocarcinoma MDA-MB-231 Cell Line 
MDA-MB-231 cell line is derived from breast adenocarcinoma and has epithelial morphology [33]. 
At low concentrations (1 and 10 μM) tebrophen did not influence growth of MDA-MB-231 cells 
(Figure 6A). At 50 μM concentration, inhibition was significant, although cells continued to propagate 
at a slow rate. In the presence of 100 μM tebrophen, cells virtually seized divisions over long periods 
of time. At this concentration, at the beginning of treatment they significantly reduced in number 
[Figure 6A,B (center)]. However, they slowly recovered so that sporadic foci of growth started to 
emerge in the culture after ~25 days [Figure 6B (right)]. 
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Figure 6. (A) Growth of MDA-MB-231 cells in the presence of tebrophen (TEB) at 
various concentrations. Growth is expressed in terms of population doublings (PD) with 
respect to the starting concentration at day 0. (B) Control with 1% DMSO only (left). Dead 
cells observed by microscope emerging at day 10 in the culture at 100 μM tebrophen 
(center). New focuses of growth of MDA-MB-231 cells in the presence of 100 µM 
tebrophen started to emerge after ~25 days in culture without reseeding (right). Bar is 
equivalent to 200 µm.  
 
The observed reduced growth rate could be a result of growth inhibition of one fraction of cells due 
to, for example, various levels of telomerase expression as it has been described in HeLa [37,39] or 
tebrophen could equally inhibit growth of all cells in the culture. In order to address this question, we 
investigated dynamics of MDA-MB-231 cells growth with or without tebrophen using DiI staining 
FACS analysis as well as SA-β-galactosidase staining and 3H-thymidine labeling index [31,40] 
(Figure 7). FACS analysis demonstrated that the entire population of MDA-MB-231 cells showed 
reduced growth rate (Figure 7A,B). Radioactive labeling index and SA-β-Gal confirmed inhibited 
growth rate since integration of radioactivity was reduced from 98.33% in control cells to 83.98% in 
tebrophen treated cells during 24 h (Figure 7C).  
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Figure 7. DiI FACS analysis of MDA-MB-231 cell growth with or without 50 µM 
tebrophen (TEB). (A) Gating strategy and sorted cells analysis. Bounded regions were 
drawn around cells according to their morphological properties on a FSC/SCC dot plot. 
Live cells were gated while dead cells and cell debris were excluded from further analysis 
and sorting. (B) DiI fluorescence intensity of positive control cells stained on the day of the 
experiment (light blue and green) and unstained negative control cells (yellow and olive). 
Control cell (dark blue) and cell treated with 50 μM tebrophen (turquoise) propagation 
after 4 days in culture. (C) Tritiated thymidine labeling index and SA--Gal activity in 
MDA-MB-231 control cells (red) and cells treated with 50 μM Tebrophen (blue). Four 
different phenotypes are described: [3H]dT+/SA--Gal−; [3H]dT−/SA--Gal+; [3H]dT+/ 
SA--Gal+; [3H]dT−/SA--Gal−. At least 1,000 cells per sample were counted for 
statistical analysis.  
 
At the same time tebrophen treated cells showed 14.55% of [3H]dT-/SA--Gal-phenotype due to 
slowed or postponed cell cycle. SA-β-Gal activity could be induced in immortal cell lines as a result of 
oxidative stress or DNA-damaging agents [41,42]. Since SA-β-Gal staining was very low in both cell 
samples, the observed effects of tebrophen could not be assigned to induced oxidative stress in these cells. 
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2.5.4. Strong Inhibitory Effect of Tebrophen on Proliferation of Prostate PC3 Cell Line 
The PC3 cell line is derived from prostate adenocarcinoma and has epithelial morphology [35]. 
These cells did not demonstrate significant inhibition of the growth rate at low concentrations of 
tebrophen (1 or 10 μM) over ~35 PDs (Figure 8A). On the contrary, at 50 or 100 µM tebrophen PC3 
cells stopped dividing and massive cell death occurred. Their number continuously declined (Figure 8B) 
and they eventually completely vanished from the culture after 39 or 19 days, respectively. 
Figure 8. (A) Growth of PC3 cells in the presence of tebrophen (TEB) at various 
concentrations. Cells at concentrations of 50 and 100 µM of tebrophen died out and were 
cleared from the culture within 39 and 19 days, respectively. (B) Dead cells observed by 
microscope at day 12 in the culture at 50 and 100 µM tebrophen. Bar is equivalent to 200 µm.  
 
Significant inhibition of the growth rate of MDA-MB-231 cells and complete clearance of PC3 
cells from the culture was somehow unexpected since tebrophen had no significant effects on the 
viability of standard cell lines HepG-2, THP-1, CHO and COS-1 and the growth of NF fibroblasts up 
to ~55 days. We wanted to check whether this inhibitory effect of tebrophen was cell specific, so 
additional tests on well-known cell lines U2OS and HeLa were performed over a longer period of time 
(30–40 days in culture). 
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2.5.5. Bone Osteosarcoma U2OS Cell Line 
The U2OS cell line is derived from bone osteosarcoma and shows epithelial morphology [36]. 
Tebrophen did not significantly influence growth rate of these cells at low concentrations (1 and  
10 μM), but at 50 or 100 μM concentrations inhibition was significant (Figure 9A). These cells 
changed their morphology, enlarged and created extensions (Figure 9B). Nevertheless, since they 
retained constant growth although at low rate, we can say that overall these cells demonstrate 
substantial resistance to tebrophen. 
Figure 9. (A) Growth of U2OS cells in the presence of tebrophen (TEB) at various 
concentrations. (B) Control cells and cells treated with 50 and 100 µM tebrophen observed 
by microscope at day 12. Bar is equivalent to 100 µm.  
 
2.5.6. Cervical Adenocarcinoma HeLa Cell Line 
The HeLa cell line is derived from cervical adenocarcinoma and has epithelial morphology [38]. 
They demonstrated very high resistance to tebrophen and grew well even in the presence of 50 or 100 µM 
tebrophen (Figure 10A). At 100 µM tebrophen, cells demonstrated some morphological changes such 
as enlargement and develop extensions. They kept enlarged phenotype throughout the experiment, but 
retained high viability and growth rate (Figure 10). 
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Figure 10. (A) Growth of HeLa cells in the presence of tebrophen (TEB) at various 
concentrations. (B) Control HeLa cells and cells with 100 μM tebrophen documented at 
day 28. Bar is equivalent to 100 µm.  
 
2.6. Radical Scavenging Activity of Tebrophen 
The observed antiproliferative effect of tebrophen may be, at least partly, due to its antioxidative 
ability based on radical scavenging, similarly to other aromatic polyphenols whose radical scavenging 
activity (RSA) is due to their OH group(s). Non-enzymatic antioxidative ability of flavonoids, 
stilbenoids like resveratrol and plenty of other diverse polyphenolic compounds, is often related to 
their biological effects [43].  
In order to test the hypothesis that RSA of tebrophen is responsible for its antiproliferative effect 
and due to the fact that there are no experimental data available for this molecule, the bond 
dissociation enthalpies (BDE) and acidities of the OH groups as well as molecular ionization potential 
(IP) were calculated and compared with the corresponding literature values [44] for the aromatic 
polyphenols showing antiproliferative effects on PC3 cancer cell line [45–47]. The calculated  
gas-phase BDE, IP and acidity values are collected in Table 1. In addition to plenty of developed  
in vitro assays [48] quantum-chemical calculations of these parameters have been extensively used for 
estimation of antioxidative capacity of chemical compounds [44]. The antioxidant properties of 
polyphenols may arise from direct reactions with various endogenous free radicals [44] and also from 
the chelation of free metals which changes metal redox potential and thus prevents it from taking part 
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in the reactions generating free radicals [49]. Antioxidants can scavenge radicals in general, by the two 
major mechanisms: 
(1) Hydrogen Atom Transfer (HAT): ArOH + R• → ArO• + RH 
and: 
(2) Single Electron Transfer (SET): ArOH + R• → ArOH•+ + R 
where R• denotes a free radical. The HAT reaction is characterized by the O–H BDE parameter.  
A weaker O–H bond, that is a lower BDE, makes the phenolic hydrogen abstraction by a biological 
free radical more favourable. In the SET mechanism, the significant parameter for the scavenging 
activity evaluation has been assumed to be IP. The lower IP value of an antioxidant makes the electron 
release and radical reduction easier. 
Table 1. Comparison of bond dissociation enthalpies (BDE), ionization potentials (IP) and 
acidities a of tebrophen and polyphenolic phytochemicals reported to induce apoptosis of 
PC3 cells. All calculated values are given in kcal/mol. 
Species BDE IP Acidity ABTS+ assay (TEAC, mM) b 
ortho-Tebrophen  82.37 169.6 326.3 NA 
para-Tebrophen 81.98 169.6 324.9 NA 
Apigenin 82.2 176.0 321.3 0.086 
Kaempferol 80.9 168.0 322.7 1.59 
Luteolin 74.5 174.4  2.18 
Quercetin 72.3 166.1 316.5 4.42 
Resveratrol 77.3 161.3 327.5 2.14 
a The energetic parameters BDE, IP and acidities of tebrophen were calculated by using the same 
equations as in the reference [44]. For molecules apigenin to resveratrol the minimal O–H BDE and 
IP values calculated at the B3LYP/6-311++G(d,p) level are taken from reference [44]. The minimal 
O-H BDE/IP/Acidity values (in kcal/mol) calculated for e.g., quercetin, kaempferol and apigenin 
with the same model as for tebrophen are 74.2/166.2/319.7, 81.6/167.2/325.9 and 83.5/175.7/322.8, 
respectively. b Experimental activities are taken from reference [50]. 
Among listed bioantioxidants (Table 1), quercetin and resveratrol have the highest antioxidant 
ability as characterized by their lowest BDE and IP values [44,51]. Apigenin has poor radical 
quenching and reduction properties, while luteolin and kaempferol are of moderate antioxidant 
activities. In comparison, tebrophen is poorly susceptible to donate hydrogen atoms to free radicals.  
It may be more likely to scavenge free radicals by SET mechanisms since its IP is between IP values 
of good and weak antioxidants. 
Since metal chelation by polyphenols often occurs through deprotonated hydroxyls, the compound 
acidity may play an important thermodynamic role [44]. The lower energy required to deprotonate the 
OH groups (less positive acidity parameter in Table 1), could result in more favourable metal chelating 
properties. Tebrophen is less acidic than most of the other polyphenols (Table 1). Although its acidity 
is similar to those of resveratrol which is known to form metal complexes [52], its reducing capacity 
was calculated to be weaker. According to the arrangement of hydroxyl and bromo groups (Figure 1), 
the metal chelating capacity of tebrophen can also be expected to be low. 
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Thus, tebrophen is estimated to be poorly active as just a hydrogen and electron donor.  
Non-enzymatic antioxidant capacity of tebrophen is quite unlikely to be responsible for its observed 
antiproliferative effects on PC3 cells. It should react with specific biological targets. As it has often 
been reported for polyphenols, tebrophen’s antioxidative activity may be due to its ability to modulate 
certain cellular signalling pathways like protein kinase pathways [43]. 
3. Discussion 
The general scope of the drug discovery platform that finally led to the results presented here was to 
identify interactions between compounds from in house compounds library and pharmacologically 
relevant targets, using available in silico and biological in vitro screening approaches. The purpose  
was to recognize additional “hidden” values of in house compounds and to create conditions for  
the implementation of new program(s) into drug discovery pipeline, which is the approach widely 
accepted today by the pharmaceutical industry [53]. By combining computational and biological 
methods, positive and reliable hits were detected in a very short time frame by using small amounts of 
reagents. In this way the whole early stage drug discovery process known as the “hit generation” was 
performed utilizing minimal resources and any duplication work was avoided. 
Further characterization of the best HTS compounds on cellular and functional assays indicated that 
an “old” drug, tebrophen (Figure 1) can exhibit quite significant interactions with “new” targets, and 
that the compound can be classified as a “promising hit” for the anti-inflammatory/cancer therapeutic area. 
At first, we were encouraged with preliminary in silico screening result since tebrophen was 
successfully docked into DPPIV catalytic pocket (Figure 2), an enzyme of significant therapeutic 
interest [15,18–20,25]. This result was confirmed by in vitro detected inhibition. DPPIV/CD26 is a  
110 kDa surface-bound ectopeptidase with intrinsic dipeptidyl peptidase IV (DPPIV) activity and 
multiple biological functions. As partially stated before, this enzyme modulates the biological 
functions of various peptides such as hormone peptides, neuropeptides and chemokines [23]. Apart 
from its catalytic activities, it interacts with proteins, for example adenosine deaminase (ADA), 
collagen, CD45 and the HIV derived protein -gp120. CD26 effects glucose metabolism through its 
DPPIV activity on glucagon-like peptide-1 (GLP-1). Its potential role as a therapeutic target in 
diabetes is of special significance from a clinical perspective [19,21,22]. It is expressed in many 
human tissues and is implicated in various biochemical processes, for example glucose homeostasis, 
activation of T lymphocytes, HIV infection and apoptosis, and it has a particularly important role in 
some chronic inflammation (e.g., rheumatoid arthritis) and neoplastic disease developments [5,18,54]. 
Some known antidiabetic drugs, such as metformin, have been considered as compounds with 
anticancer properties [55], acting through the kinase pathways, but when applying them in 
combination with cisplatin-based drugs, they can interfere with the cancer cells survival [56]. 
Accordingly, the class of targets included in our screening platform was tyrosine kinases. Protein 
kinases are a large family of enzymes that mediate the response of eukaryotic cells to external stimuli 
by phosphorylation of hydroxyamino acids. They play an essential role in many signaling pathways, 
and therefore have the potential to contribute to diseases ranging from cancer and inflammation to 
diabetes and cardiovascular disorders and many biological processes like cell growth and survival. 
Recent investigations have revealed that there are over 500 human kinases, making them the most 
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populated class of targets, and many of them are targets for naturally derived compounds from plants, 
like polyphenols [12]. Phosphorylation of certain tyrosine residues changes the enzymatic activity of 
tyrosine kinases, thus regulating specificity for substrate binding, localization and recruitment of 
downstream signaling proteins. In primary single-target based screening, tebrophen was found to 
inhibit the two closely related kinases, Lck and ZAP-70, deriving from T-lymphocytes, in low μM 
range (Figure 3A). Results obtained for Lck were in the same range as previously reported results of 
testing natural polyphenols apigenin, myricetin and quercetin [13]. Assuming that structural basis for 
the inhibition of ZAP-70 activity might be similar to the that of cyclin-dependant kinases and Src 
kinases, which was later confirmed [57], and that many polyphenols like flavonoids have shown 
inhibition of Src and cyclin dependent kinases [47,58,59], logical consequence was further exploration 
of the potential of tebrophen, poorly investigated halogenated polyphenol considered as an antiviral 
drug [60]; in the framework of relevant therapeutic area. Tebrophen was considered as a non-cytotoxic 
compound according to the results obtained after its testing in standard cell lines (THP1-1, HepG-2, 
COS and CHO) applying MTS assays during 24 h. 
In the oxidative burst assay, tebrophen exhibited an antioxidative effect, although not pronounced 
(Figure 3B). This result was confirmed by quantum-chemical calculations according to which tebrophen 
possesses no considerable radical scavenging and metal chelation activities (Table 1). Such results 
confirmed our observations that most probably tebrophen acts through interaction with specific target(s).  
Bearing in mind all results obtained, we decided to test the compound in functional and tailor-made 
cellular assays in order to access its capacity to stop proliferation of specific cancer cells in  
which DPPIV plays an important role acting particularly on glucagon-like peptide-1 (GLP-1) and  
glucose-dependent insulinotropic polypeptide (GIP), and to compare these results with other relevant 
cancer cell lines. We tried to apply a relevant approach to test the compound effect over a long period 
of time in parallel onto primary normal cell line and different cancer cell lines. This enabled us to build 
some conclusions on tebrophen specificity. Growth and viability of all considered cell lines were 
followed over extended periods of time (up to 50 PD) which could be relevant for potential application 
in therapy. In this respect, experiments on normal human skin fibroblasts NF or MJ90 (Figures 4 and 5) 
did not show any difference in growth rate or sudden onset of cell senescence [61] over approximately 
14 PDs in the presence of 50 µM tebrophen comparing to the control cells. This clearly demonstrates 
that the drug itself does not affect normal cell growth.  
On the contrary to normal cells, tebrophen interferes in cancer cell propagation. Inhibitory effects of 
tebrophen were investigated on growth and viability of the four cancer cell lines of various origins: 
MDA-MB-231 (breast cancer), PC3 (prostate cancer), U2OS (osteosarcoma) and HeLa (cervical 
carcinoma). These cells differed in their resistance to inhibitory effects of tebrophen. Most of them 
showed reduced growth rates, while PC3 underwent massive cell death and terminated culture 
propagation at tested concentrations of 50 and 100 µM tebrophen. 
Low concentrations of tebrophen (1 or 10 µM) had no influence on the growth rate of MDA-MB-231 
(Figure 6). At 50 µM concentration, the inhibitory effect of tebrophen was significant, but MDA-MB-231 
cells remained viable and dividing. At 100 µM tebrophen, cells virtually ceased dividing over a long 
period of time (~25 days). During this period, most cells died out which dramatically reduced their 
number in the culture. However, some of them remained quiescent and eventually slowly recovered so 
that sporadic foci of growth started to emerge in the culture. Therefore MDA-MB-231 cells could 
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undergo some modifications and regain ability to divide (Figure 7). We concluded that tebrophen has a 
moderate effect on the propagation of MDA-MB-231 cells. 
In comparison to this, tebrophen did not show such strong effects on U2OS and HeLa cells. 
Precisely, low concentrations (1 and 10 µM) of tebrophen did not significantly influence growth of 
U2OS cells (Figure 9), although at 50 or 100 µM tebrophen inhibitory effects were more obvious. 
Overall U2OS cells demonstrated substantial resistance to tebrophen. HeLa cells also exhibited high 
resistance to tebrophen (Figure 10). They maintain high viability and growth rate even at the highest 
concentration of 100 µM tebrophen.  
The most interesting effect of tebrophen was observed on PC3 cells (Figure 8). They did not 
demonstrate very significant inhibition at low concentrations (1 or 10 µM), but at 50 or 100 µM of 
tebrophen present in the culture, they ceased division over long periods of time (about 39 or 19 days, 
respectively) and finally died. Thus, tebrophen has greater inhibitory effects on male cells (PC3) than 
on female cells (NF, HeLa, MDA-MB-231, U2OS) which could be attributed to hormone dependence 
of different cancer cells [62]. 
The results obtained with tebrophen on PC3 cells are in line with the results reported by  
Knowles et al. [47], where naturally occurring flavonoids have shown their complete retardation 
(using 100 μM quercetin) and suppression of growth (using apigenin and myricetin). In addition, not 
only natural (bromo)phenols, but also their synthetic analogs have also shown identical or even better 
in vitro protein tyrosine kinase inhibitory activity (μM) [63]. Thus, this could indicate pathway in 
searching for new chemical entities that could be further developed as therapeutic/chemopreventive 
agents for prostate cancer.  
4. Experimental 
4.1. Tebrophen 
Tebrophen was purchased from the InterBioScreen (Chernogolovka, Russia) and VitasM (Moscow, 
Russia) companies, and was prepared as 10−2 M stock solution using pure DMSO.  
4.2. In Silico  
4.2.1. Molecular Docking 
The binding of tebrophen onto DPPIV was determined by a molecular docking procedure designed 
for in silico screening [3]. The calculations were carried out by the program FlexX, ver. 1.12.2 L [64] 
with its default setting. The docking was done by using the X-ray 2.5 Å structure of the extracellular 
region of DPPIV in complex with the inhibitor valine-pyrrolidide [26] (PDB code 1N1M [65]) and 
DrugScore scoring function [66]. The binding site was defined as a sphere with an origin at the 
hydroxyl O-atom of the catalytic amino-acid residue Ser630 and a radius of 10 Å. Input conformation 
of Tebrophen was pre-minimized by a Tripos force field with Gasteiger-Hückel charges and  
distance-dependent dielectric constant ε = ε(4r) (Tripos Inc., 2003) using a gradient of 0.05 kcal/mol Å 
as a terminating criterion. 
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4.2.2. Quantum-Chemical Calculations 
The equilibrium geometries of tebrophen in its unionized, oxidized radical and radical cation as 
well as anionic ground electronic states were fully optimized at the B3LYP/6-31+G(d,p) level in the 
gas phase. The minima on the potential energy surfaces were confirmed by vibrational frequency 
calculations. Both ortho and para hydroxyl (OH) groups were considered. All calculations were done 
with the Gaussian 03 program suite [67]. 
4.3. In Vitro ZAP-70 and Lck Kinase, and DPPIV Inhibition Protocols 
ZAP-70 and Lck protein kinases were expressed in the Sf9 (Spodoptera frugiperda ovary cell) 
baculovirus expression system, and thereafter purified using chromatography methods. Purification 
and characterization were performed according to literature protocols [68–70]. 
The substrates o-phenylenediamine, HEPES, MgCl2, BSA, adenosine 5'-triphosphate disodium  
salt (ATP) and kinase substrate [random polypeptide copolymer Poly Glu:Tyr (4:1)], were obtained 
from Sigma (St. Louis, MO, USA). Peroxidase-labeled anti-phosphotyrosine antibody PY20 (mouse) 
was obtained from Calbiochem (San Diego, CA, USA). Tween 20 (polyoxyethylene sorbiton 
monolaureate) was obtained from Pharmacia (Uppsala, Sweden). MnCl2 and H2O2 were obtained from 
Merck (Whitehouse Station, NJ, USA). DTT (dithiothreitol) was obtained from Bio-Rad (Hercules, 
CA, USA). Measurements were performed by a Multiscan Ascent spectrophotometer (ThermoLabSystem, 
Helsinki, Finland). 
In vitro inhibitions of ZAP-70 and Lck protein kinases by tebrophen were monitored according to 
the previously published ELISA method [4,13]. Briefly, phosphorylation of the substrate was 
monitored by an immunochemical reaction, where phosphorylated substrate residues were detected by 
specific immunocomplex and absorbance was measured at 490 nm. ELISA experiments were 
conducted in 96-well Dynex Immulon 2 HB microtiter plates (flat bottom, transparent). Peptide 
substrate in constant (10 µg/well) concentration was coated to the plate. After washing, buffer solution 
with ATP was added to each well. Compounds were added into wells in final doses that ranges from 
10−3 mol/L to 10−11 mol/L. ZAP-70 and Lck protein kinases was added in 100 ng/well concentration 
and kinase reaction lasted 1 minute. After washing, blocking of the wells with 1% BSA in TBS was 
performed. Peroxidase-labeled anti-phospho-tyrosine antibody was then added and incubated for  
40 min. After washing, peroxidase substrate [71] was added and the reaction was stopped after 20 min 
with 5 M H2SO4. Absorbance was measured at 490 nm. The IC50 value was calculated by using 
GraphPad Prism software, v. 3.02.  
DPPIV enzyme was obtained from R&D systems (Minneapolis, MN, USA), and activity of the 
compound was tested using H-Gly-Pro-pNA tosylate (Bachem, Bubendorf, Switzerland) as a substrate. 
The enzymatic reaction was performed in 100 μL of buffer containing 50 mM Tris, 150 mM NaCl at  
pH 7.9. The percent of inhibition was determined after 60 min. 
4.4. Cytotoxicity Assay 
Cytotoxicity assays on four different cell lines (THP-1, COS, HepG2, CHO) were run routinely as a 
part of secondary screening and compound profiling. Cancer cell lines were purchased from the 
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ECACC: THP-1 (human monocyte leukemia) ECACC-88081201, HepG2 (human hepatocytes, 
epithelial) ECACC-85011430, CHO (chinese hamster ovary, epithelial) ECACC-85050302, and COS-7 
(green african monkey kidney, fibroblasts) ECACC-87021302. Cells were maintained in complete 
RPMI 1640 medium (Institute of Immunology, Zagreb, Croatia) supplemented with 10% fetal bovine 
serum (BioWest, S04382S1810) at 37 °C in a 5% CO2 atmosphere. Cytotoxicity assay was performed 
by using the MTS CellTiter 96® AQueous One Solution Cell Proliferation Assay (G358B, 18824201, 
Promega, Madison, WI, USA). Each culture in 96-well plate contained 50 000 (for HepG2, CHO and 
COS-7 or 75000 for THP-1) cells. Cultures exposed to tested compounds were incubated for 24 h at  
37 °C in 5% CO2. Thereafter, 15 μL of MTS reagent [30] was added directly to the cell lines. After an 
additional 2 h of incubation at 37 °C in 5% CO2, the absorbance was recorded at 490 nm using a 
spectrophotometric plate reader (Ultra, TECAN, Mannedorf, Switzerland). The method was 
programmed for the TECAN robotic system in GEMINI pipetting software [4]. 
4.5. Oxidative Burst Assay 
The effect of tebrophen on oxidative burst was investigated in vitro with oxidative burst assay in 
human polimorphonuclear (PMN) cells. Assay was done in 96 well plates (Wallac, Turku, Finland, 
type “black & white”, flat bottom, 1450-581, 50,000 cells/100 μL of DMEM). The test compound was 
added to the cells in the final concentration of 50, 25, 12.5, 6.25 and 3.125 μM and mixed with 50 μL 
of luminol (5-amino-2,3-dihydro-1,4-ftalazindione, 0.25 mg/mL, Sigma, A-4685). Luminol as a 
detector of oxidative burst reacts with superoxide and light is produced as one of the reaction  
products. Subsequently, 50 μL of stimuli, phorbol-12-myristate acetate, PMA, 33 ng/mL, Sigma, P-8139, 
125K1091) or zymozan (2 ng/mL, Sigma, Z-4250), were added. Signal was measured after 60 min of 
incubation of the cells with the test substances and stimulus. All experiments were done in duplicate. 
The control contained the same DMSO concentration as the test wells. 
4.6. Functional Assays 
4.6.1. Cell Culture 
Normal human skin fibroblasts NF [31], normal human skin fibroblasts MJ90 [32], HeLa cell line 
derived from cervical adenocarcinoma [38], U2OS cell line derived from bone osteosarcoma [36], 
MDA-MB-231 cell line derived from breast adenocarcinoma [33] and PC3 cell line derived from 
prostate adenocarcinoma [35] were grown in high glucose Dulbeco’s modified Eagle’s medium 
(DMEM; Sigma) supplemented with 10% fetal calf serum (Gibco, Grand Island, NY, USA) at 37 °C 
and 5% CO2. Following reseeding, cells were treated with 0, 1, 10, 50 and 100 μM of tebrophen and 
pure solvent dimethyl sulfoxide (DMSO, Sigma) as a control. When cells reached confluency they 
were trypsinized, counted for population doubling calculation and split for reseeding, usually in a  
1:8 ratio. Population doubling (PD) was calculated according to the formula: PD = log (N0 cells 
harvested/N0 cells seeded)/log2. Any changes in cell morphology or growth were photographed for 
documentation. 
Peripheral blood leukocytes were obtained from healthy volunteers (Department of Transfusion 
Medicine, Zagreb, Croatia). Fresh blood was mixed with dextran (5 mL 3% dextran T-500, Amersham 
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Biosciences, Uppsala, Sweden, SAD/7 mL of blood), albumin (0.05% albumin A-6918, Sigma) and 
PBS with glucose (1.5 mL PBS with 0.18% glucose/7 mL of blood). After 30 min of sedimentation in 
50 mL syringes, plasma was extracted.  
Neutrophils (PMN cells), were isolated by using fycoll (30 mL of plasma/15 mL fycoll;  
Ficoll-PaqueTMPlus, Amersham Biosciences, Uppsala, Sweden, 17-1440-02), after 30 min of spin on 
1,800 rpm at room temperature. After removal of supernatant, PMN cells with erythrocytes were 
resuspended in 7 mL Milli-Q water, and 7 mL of 1.8% NaCl is added. After 10 min spin on 1,800 rpm 
at room temperature, supernatant was removed and PMN cells were re-suspended in 5 mL 
supplemented RPMI 1640 (Institute of Immunology, Zagreb, Croatia). 
Peripheral blood mononuclear cells were isolated by using Histopaque 1077 (Sigma Diagnostics, 
St. Louis, MO, USA) or fycoll (15 mL Histopaque 1077/30 mL blood). After 30 min spin at 400 g, 
plasma above cells is removed. Peripheral blood mononuclear cells were collected with pipette, and 
diluted with PBS in clean tube. After 10 min spin on 1,300 rpm at room temperature, supernatant was 
removed and cells were resuspended in supplemented RPMI 1640 medium and fetal bovine serum 
(FBS). After determination of concentration, 500 μL of ice cold 20% DMSO in supplemented RPMI 
1640 was added to the cells (1:1 ratio), and cells were frozen on −80 °C in concentration of 10 × 106 
cells/vial for future use. 
4.6.2. SA-β-galactosidase Staining and 3H-Thymidine Labeling Index 
About 105 cells were seeded in 25 cm3 bottle and incubated at 37 °C, 5% CO2. After approximately 
24 h, 3H-thymidine was added at a concentration of 10 µCi/mL and incubation continued for another 
24 h. Following this treatment, cells were fixed in 1% glutaraldehyde for 10 min, washed in PBS  
2 × 5 min and stained for SA-β-Gal activity at pH 6.0 over 18 h as described previously [40,72]. For 
autoradiography, cells were washed 2 × 5 min in PBS, 2 × 5 min in 70% ethanol and dried at room 
temperature for several hours. In a dark room, fixed cells were overlaid with liquid photographic 
emulsion (Ilford Scientific Product, Knutsford, UK), wrapped in aluminum foil and stored at 4 °C for 48 h. 
Preparations were processed in standard Kodak developer and universal fixer. More than 1,100 cells 
were scored for statistical analysis. 
4.6.3. DiI Staining and Flow Cytometry 
For fluorescent staining, an appropriate number of cells (1.5–2 × 106) were trypsinized and spun 
down at 1,000 rpm in a swing-rotor laboratory centrifuge. Cells were than washed twice in PBS, 
resuspended in 10 mL of serum free DMEM medium containing 5 µM solution of DiI  
(1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanineperchlorate, Molecular Probes, Eugene, OR, 
USA) and incubated for 20 min at 37 °C [31]. To remove excess of dye, cells were washed twice and 
cultured in the dark, wrapped in aluminum foil at 37 °C, 5% CO2. After 4 days in culture at ~80% 
confluence cells were trypsinized, washed twice in freshly prepared washing/staining buffer (PBS 
containing 2% FBS and 0.02% EDTA (Sigma) and resuspended in the same buffer at final 
concentration of 2 × 107 mL–1. Cells were kept on ice until sorting. Positive control cells were stained 
and washed the same way on the day of sorting and placed on ice until sorting. Negative control cells 
were trypsinized and without staining resuspended in washing/staining buffer. Cells were analyzed on 
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a Cell sorter (FASCCalibur, Becton Dickinson, Mountain View, CA, USA) using CellQuest Software 
(Beckton Dickinson). Two measured parameters, FSC (forward-scattered light) and SSC (side-
scattered light) were detected with linear signal amplification. DiI specific fluorescence emission was 
detected on the FL2 channel using a 570/30 dichroic emission filter and logarithmic signal 
amplification. Results were analyzed by the Cell Quest Software program (Becton Dickinson). 
5. Conclusions 
By in vitro screening the already known antiviral drug, tebrophen has been revealed to inhibit 
tyrosine kinases-Lck and ZAP-70, and hydrolase-dipeptidyl peptidase IV at μM levels. This 
halogenated polyphenol has also been shown to be non-cytotoxic and to have no significant effects on 
proliferation of healthy primary human cells. However, it has been found to inhibit propagation of 
various immortal cells MDA-MB-23, PC3, U2OS and HeLa after longer period of time. Its different 
effects on various cancer cell lines could be attributed to specificity of these cells as they developed 
different surviving mechanisms of immortality [62] and since according to measurements and 
calculations it has no notable non-enzymatic antioxidant activity. Subsequently, while tebrophen 
eliminates PC3 cells and inhibits other studied cell line growth, it is suggested as a starting lead 
molecule for the design of more soluble derivatives with specific anticancer activity. For that purpose 
testing on several different prostate cell lines and detailed mechanistic study including tyrosine kinases [63] 
have to be performed.  
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